NCT03537378Completed
Hybrid APC Therapy in Early Central Lung Neoplasms
A Multi-Center Clinical Study of the Hybrid APC Therapy in Early Central Lung Neoplasms
Source: ClinicalTrials.gov · Last updated 10 Jul 2025
Brief summary (registry, in English)
1.1 Aims：This cohort study aims to investigate the clinical value of Hybrid APC for treatment of early central lung neoplasms. 1.2 methods：A total of 30 patients with early central lung neoplasms will be included in this open, multicenter, prospective study. Primary observation endpoint is recorded at 3 months follow-up, and after 3 months patients could be continued to follow up. The data are expressed in terms of mean and percentage. The categorical variables are analyzed by chi-square test, and the four table data is analyzed using the exact probability method. The continuous variable analysis is used by t test. Statistical analysis is performed with SPSS 20.0 software. P \< 0.05 is considered statistically significant.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 15 May 2018
- Start date
- 26 Dec 2018
- Primary completion date
- 22 Feb 2022
- Lead sponsor
- Jiayuan Sun
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT03537378
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From 26 Dec 2018 to the primary completion date, 22 Feb 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe bleeding tendency
Other
- Patients with severe cardiopulmonary dysfunction or other contraindication can not tolerate endoscopic examination and treatment
- Poor compliance
- Unstable vital signs
- Investigators consider subjects should not be included because of specific situations
Who the study is looking for
- Bronchoscopy and fluorescence bronchoscopy found endoluminal growth lesions of upper segmental bronchus. AFB indicates malignant possibility.
- Size ≤ 20 mm
- Flat, nodule or polypoid type
- Negative imaging: HRCT indicates no tumor in lung and lymph node enlargement; or PET-CT finds no lesions in lung or suspicious lymph node tumors involve.
- Clinical stage: Tis or T1N0M0
- High-grade intraepithelial neoplasia (including severe atypical dysplasia and carcinoma in situ) mucoepidermoid carcinomaand ,squamous cancer and etc. confirmed by biopsy histopathology
- High-frequency EBUS indicates the depth of lesions is cartilage endomembrane or internal part of adventitia of tracheal membranous part
- Patients are not suitable for surgery or refuse surgery
- Inform consent is available
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.